Dexcom vs Regeneron Pharmaceuticals

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (77 vs 79)
Dexcom logo

Dexcom

LeaderHealthcare Tech

Enterprise

San Diego CGM diabetes technology (NASDAQ: DXCM) ~$3.9B 2024 revenue; G7 prescription CGM market leader, Stelo OTC CGM launched 2024, $75M Oura Ring investment/integration competing with Abbott FreeStyle Libre.

AI VisibilityBeta
Overall Score
B77
Category Rank
#67 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
71
Gemini
72

About

Dexcom, Inc. is a San Diego, California-based diabetes management technology company — publicly traded on NASDAQ (NASDAQ: DXCM) as an S&P 500 Health Care component — developing and commercializing continuous glucose monitoring (CGM) systems for people with Type 1 diabetes, Type 2 diabetes, and pre-diabetes through approximately 9,000 employees worldwide. Dexcom's G7 CGM system (a small wearable sensor and transmitter worn on the body that measures glucose continuously every 5 minutes without fingerstick calibration) is the market-leading prescription CGM for insulin-using patients — enabling tight glucose management that prevents hypoglycemic episodes, reduces A1c levels, and improves outcomes for the 8+ million US patients using insulin. In 2024, Dexcom launched Stelo — the first FDA-cleared over-the-counter CGM in the United States, requiring no prescription and targeting the approximately 25 million US adults with Type 2 diabetes who do not use insulin, pre-diabetes patients, and health-conscious consumers seeking metabolic insights. The Stelo OTC CGM integrates with the Oura Ring (wearable health tracking) through a strategic partnership announced in November 2024, with Dexcom investing $75 million in ŌURA and the companies launching Stelo integration in the Oura app — giving users 24/7 glucose insights alongside sleep, heart rate, and activity data from the Oura Ring. Dexcom reported full year 2024 revenue of approximately $3.9 billion, with continued CGM market penetration driving growth.

Full profile
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

AI VisibilityBeta
Overall Score
B79
Category Rank
#30 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
76
Gemini
75

About

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Full profile

AI Visibility Head-to-Head

77
Overall Score
79
#67
Category Rank
#30
71
AI Consensus
73
stable
Trend
stable
82
ChatGPT
77
71
Perplexity
76
72
Gemini
75
75
Claude
85
80
Grok
74

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.